Kinera’s lead therapeutic CMK103 is a recombinant human form of MK protein for use in cardiac ischemia (heart attack). Treatment with CMK103 significantly enhances survival in pre-clinical models of cardiac ischemia.  In pre-clinical animal studies, MK reduced infarct size by preventing apoptotic death in heart muscle cells that had been cut-off from blood supply. MK treatment also prevented ventricular remodelling and improved cardiac function in the weeks after infarction. No MK toxicities have been observed in animal studies to date. Further pre-clinical and manufacturing studies of CMK103 are currently underway.


Treatment with midkine significantly reduces mortality and improves survival in preclinical models of myocardial infarction